Company
Avidity
Delivering a New Class of RNA Therapeutics
Also known as Avidity Biosciences, Avidity Biosciences, Inc.
- Status
- Operatingas of 2026-09-20
- Business model
- B2B
- Legal name
- Avidity Biosciences, Inc.
- aviditybiosciences.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
At Avidity Biosciences, we are driven by our mission: to profoundly improve people’s lives by revolutionizing a new class of targeted RNA therapeutics. We are doing this by realizing the broad and disruptive potential of our Antibody Oligonucleotide Conjugates (AOC™) platform. Beginning with our muscle disease franchise, our programs tackle the root cause of disease.
Funding snapshot
- Total raised
- $528MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $400M2024-03-04
Funding rounds
- Round, 2024
- $400M2024-03-04, SEC form D sold, 45 investors
- Round, 2019
- $101M2019-11-08, SEC form D sold, 28 investors
- Round, 2016
- $18M2016-12-21, SEC form D sold, 21 investors
- Round, 2014
- $9.1M2014-01-31, SEC form D sold, 36 investors
Loading relationship preview